GOSS Gossamer Bio
- 1.120
- +0.030+2.75%
- 1.148
- +0.028+2.53%
Gossamer Bio News
Why Is Gossamer Bio, Inc. (GOSS) the Best One-Dollar Stock to Buy Now?
Gossamer Bio (GOSS) Receives a Buy From Piper Sandler
Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
Gossamer Bio And 2 Other Stocks Under $2 Insiders Are Buying
Express News | Gossamer Bio Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $9
Express News | Gossamer Bio Shares Are Trading Higher After Oppenheimer Initiated Coverage With an Outperform Rating and a Price Target of $9
Gossamer Bio Initiated at Outperform by Oppenheimer
Express News | Oppenheimer Initiates Coverage On Gossamer Bio With Outperform Rating, Announces Price Target of $9
Gossamer Bio(GOSS.US) Officer Buys US$250.28K in Common Stock
Gossamer Bio a New Outperform at Oppenheimer on Seralutinib for PAH
Bryan Giraudo Bought 21% More Shares In Gossamer Bio
Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gossamer Bio(GOSS.US) Officer Buys US$59,110 in Common Stock
Gossamer Bio(GOSS.US) Officer Buys US$15,050 in Common Stock
Gossamer Bio Is Maintained at Buy by Goldman Sachs
Express News | Gossamer Bio Shares Are Trading Higher After Competitor Aerovate Therapeutics Reported Topline Results From the Phase 2b Portion of IMPAHCT Trial of AV-101 for Pulmonary Arterial Hypertension
Goldman Sachs Maintains Gossamer Bio(GOSS.US) With Buy Rating, Maintains Target Price $8
12 Health Care Stocks Moving In Tuesday's After-Market Session
Buy Rating Reaffirmed for Gossamer Bio on Seralutinib's Promising Clinical Data and Future Prospects
HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $10 Price Target
Analysis
Price Target
No Data
